Group III metabotropic glutamate receptor (Group III mGluR)

Group III metabotropic glutamate receptors are a subfamily of G protein-coupled receptors (GPCRs) that respond to the major excitatory neurotransmitter, glutamate[3][7]. This group comprises four subtypes: mGluR4, mGluR6, mGluR7, and mGluR8. Most group III mGluRs are mainly localized on presynaptic neurons, where they function as auto- and hetero-receptors, inhibiting neurotransmitter release and modulating synaptic plasticity primarily by downregulating cAMP production via Gi/o protein signaling[3][7][9]. They play key roles in brain physiology and are implicated in several pathologies, including Parkinson’s disease, epilepsy, anxiety, mood disorders, pain, and disorders of vision (mGluR6 in retina)[2][3][5][8]. While drug development is still emerging due to early limitations in selective pharmacology, a number of ligands (e.g., L-AP4, PHCCC, ACPT-I) have demonstrated proof-of-concept for these receptors as therapeutic targets[2][5][8]. Safety and efficacy in humans require further study, although experimental models demonstrate neuroprotection, anti-parkinsonian effects, and potential benefit for neuropsychiatric and pain disorders[2][3][5][8].

Other names

mGluR4mGluR6mGluR7mGluR8Group III mGlu receptorsGroup III mGluR

Agonists and positive allosteric modulators activate/increase the function of group III mGluRs, leading to inhibition of neurotransmitter release via Gi/o protein-dependent inhibition of adenylyl cyclase and downstream cAMP signaling[3][7]. Negative modulation or antagonism leads to increased neurotransmitter release. These actions mediate neuroprotective, antipsychotic, antidepressant, analgesic, anxiolytic, and anti-parkinsonian effects, depending on the neuronal circuit and receptor subtype[2][5][8].